CVRx to Present at the Jefferies Global Healthcare Conference in London
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced that management will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov 18, 2025.
The presentation is scheduled for 8:00 a.m. GMT / 4:00 a.m. ET and will be available live via audio webcast on the company investor relations site at ir.cvrx.com.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, CVRX declined 3.57%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.3% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $256M at that time.
Data tracked by StockTitan Argus on the day of publication.
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025. The Company is scheduled to present at 8:00 a.m. (GMT) / 4:00 a.m. (ET) the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
When will CVRx (CVRX) present at the Jefferies Global Healthcare Conference in London?
What time is the CVRx (CVRX) presentation on Nov 18, 2025?
How can investors watch CVRx (CVRX) present at Jefferies on Nov 18, 2025?
Will CVRx (CVRX) provide a replay of the Jefferies presentation?
Who from CVRx (CVRX) is scheduled to present at the Jefferies Global Healthcare Conference?
Does the CVRx (CVRX) announcement include financial or clinical data for the Jefferies presentation?
